{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gardasil+Vaccine&page=3",
    "query": {
      "intervention": "Gardasil Vaccine",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 68,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gardasil+Vaccine&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gardasil+Vaccine&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T07:25:25.269Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00423046",
      "title": "Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Papillomavirus",
        "Papillomavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gardasil ® (Merck & Co. Inc)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 1106,
      "start_date": "2007-01-24",
      "completion_date": "2012-05-14",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 40,
      "location_summary": "Chandler, Arizona • San Diego, California • San Francisco, California + 36 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "West Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423046"
    },
    {
      "nct_id": "NCT01092195",
      "title": "Gardasil Vaccination in Post Stem Cell Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gardasil Vaccine",
        "Stem Cell Transplant",
        "Immunogenicity"
      ],
      "interventions": [
        {
          "name": "Gardasil",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 64,
      "start_date": "2010-06-02",
      "completion_date": "2016-07-19",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01092195"
    },
    {
      "nct_id": "NCT03083249",
      "title": "Gardasil Knowledge",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HPV"
      ],
      "interventions": [
        {
          "name": "Gardasil",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Sarah Hostetter, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "26 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 26 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2017-02-01",
      "completion_date": "2018-06-01",
      "has_results": false,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03083249"
    },
    {
      "nct_id": "NCT01505049",
      "title": "Immune Memory After Papillomavirus Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "quadrivalent HPV vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 203,
      "start_date": "2012-01",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-07-21",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01505049"
    },
    {
      "nct_id": "NCT05557370",
      "title": "Immunogenicity of HPV Vaccine in Transplant Recipients.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Diseases",
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Human Papilloma Virus vaccine (GARDASIL 9)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-06-01",
      "completion_date": "2035-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05557370"
    },
    {
      "nct_id": "NCT03051516",
      "title": "HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "High Grade Anal Canal Intraepithelial Neoplasia",
        "High Grade Vulvar Squamous Intraepithelial Lesion"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Recombinant Human Papillomavirus Nonavalent Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "27 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "27 Years to 69 Years"
      },
      "enrollment_count": 188,
      "start_date": "2017-08-01",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Seattle, Washington",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03051516"
    },
    {
      "nct_id": "NCT01276184",
      "title": "Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HPV Vaccines"
      ],
      "interventions": [
        {
          "name": "SMS Text Message",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "26 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 26 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2011-01",
      "completion_date": "2016-06-15",
      "has_results": true,
      "last_update_posted_date": "2021-07-14",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01276184"
    },
    {
      "nct_id": "NCT05119855",
      "title": "Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Papillomavirus Infections",
        "Coronavirus Disease (COVID-19)"
      ],
      "interventions": [
        {
          "name": "9vHPV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273 Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "9 Years to 11 Years"
      },
      "enrollment_count": 165,
      "start_date": "2022-03-28",
      "completion_date": "2023-12-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05119855"
    },
    {
      "nct_id": "NCT00829608",
      "title": "Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "Human Papillomavirus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-01",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2016-10-05",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829608"
    },
    {
      "nct_id": "NCT00730704",
      "title": "Acceptance of Human Papillomavirus Vaccination in Postpartum Women",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Papilloma Virus",
        "HPV",
        "Post Partum"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "26 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 26 Years · Female only"
      },
      "enrollment_count": 150,
      "start_date": "2009-05",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2012-11-05",
      "last_synced_at": "2026-10-05T07:25:25.269Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730704"
    }
  ]
}